Clarivate Q3 Revenue Misses by Wide Margin; Guidance Sets 2026 Revenue Near $1.97B
CLVT is trading near its 52-week low of $1.42 (9.2% above the low).
Summary
Clarivate's Q3 revenue came in at $481.60 mln against a $566.77 mln consensus, a wide miss, while adjusted EPS of $0.21 beat the $0.18 estimate and adjusted EBITDA of $218.20 mln fell short of $244.26 mln. The top-line weakness tracks the completed $600M divestiture of the Life Sciences & Healthcare business to Altaris, which closed in early October and left a leaner continuing business. Underneath the headline, organic subscription revenue rose 1.5% and organic ACV grew 1.8%, but transactional revenue fell on product wind-downs and customer migration to subscriptions. Management guided 2026 revenue to $1.965-1.985 bln, adjusted EBITDA to $865-885 mln and adjusted diluted EPS to $0.73-0.77. At a $1.55 share price the stock is already priced for trouble, but a revenue miss this wide against a still-shrinking top line keeps the pressure on.
At the time of this announcement, CLVT was trading at $1.55 on NYSE in the Technology sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $1.42 to $3.87. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.